Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
dLocal Limited, a fintech company specializing in payments across emerging markets, will release its first quarter 2026 financial results on May 14, 2026. The company will host a conference call and webcast that evening to discuss the results.
BioAtla, Inc., a clinical-stage biotechnology company, announced a 50-for-1 share consolidation effective April 6, 2026, aimed at increasing its stock price to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The consolidation aligns with an approved merger where every fifty shares will convert into one share of common stock. Bi…
BriaCell Therapeutics Corp. announced that its majority-owned subsidiary BriaPro Therapeutics Corp. completed the acquisition of an exclusive license to develop and commercialize Soluble CD80 (sCD80), a novel biologic agent for cancer treatment. The license was originally secured from the University of Maryland, Baltimore County, and the transactio…
Connect Biopharma shared strong financial results and significant clinical progress in 2025 and early 2026 for rademikibart, their lead drug candidate targeting inflammatory diseases such as asthma, COPD, and atopic dermatitis. The company reported positive Phase 1 clinical data showing rapid and sustained lung function improvement with IV rademiki…
Datacentrex, a Nasdaq-listed digital infrastructure company specializing in Scrypt compute assets, closed a $20.17 million public offering by selling common stock and pre-funded warrants at $2.00 per share. The net proceeds will be utilized for working capital and general corporate purposes, supporting the company's operations and strategic initiat…
MaxCyte has granted inducement stock options and restricted stock units to Parmeet Ahuja in connection with his appointment as CFO. The awards comprise 375,000 stock options and 187,500 RSUs, vesting over four years, in compliance with Nasdaq Listing Rule 5635(c)(4).
nCino, a leading provider of banking technology solutions, announced the appointment of Keith Kettell as Chief Revenue Officer. Kettell brings extensive experience in scaling revenue organizations in financial services technology, previously contributing at Salesforce, PagerDuty, and Alloy. His hiring aligns with nCino's ambitions to accelerate gro…
Aqua Metals reported significant 2025 progress including refinement of commercialization strategy for its AquaRefining™ technology, expansion of product capabilities in lithium, nickel, and mixed hydroxide products, and successful pilot-scale recycling demonstrations. The company strengthened its financial position through capital raises, strategic…
Rekor Systems, a U.S.-based leader in AI-enabled roadway intelligence systems, reported a 5% increase in 2025 revenue to $48.45 million, expanded gross margins to 56%, and a 38% reduction in adjusted EBITDA loss. The company achieved positive operating cash flow in Q4 and has shifted to a pragmatic, product-focused model, positioning itself for sus…
Yimutian Inc. has opened its first Wolaicai Agricultural Service Station in Henan Province, marking the start of a farm-level integrated service platform combining agricultural input supply, agronomic advisory, and crop offtake. The station generated strong initial orders, and the company aims to expand to hundreds of locations in key Chinese agric…
Sportsman's Warehouse Holdings, Inc. announced Q4 and full fiscal year 2025 financial results featuring a modest 1% increase in same store sales for the fiscal year, a reduction of inventory by 8.5%, and a 6.1% decrease in net debt. Despite these operational improvements and a return to positive same store sales growth for the first time since 2020…
NextCure, Inc. announced that an abstract for their investigational antibody drug conjugate SIM0505 has been accepted for presentation at the ASCO 2026 meeting. SIM0505 targets Cadherin-6 with a proprietary topoisomerase 1 inhibitor payload and is currently in a Phase 1 clinical trial for advanced solid tumors, including platinum resistant ovarian …
Femasys Inc. announced a 40.8% increase in 2025 sales driven by FemBloc product sales, clinical trial initiation for FDA approval, new regulatory certifications, and strategic partnerships to expand commercialization globally. Despite a net loss, the company strengthened its balance sheet with $12 million financing and has cash to fund operations i…
Skeena Gold & Silver reports achieving 49% completion of its Eskay Creek Gold-Silver Project with initial production expected in Q2 2027. The project's updated construction budget stands at US$659 million, up from the 2023 estimate of US$560 million, due to inflation, enhanced environmental and permitting requirements, and design updates. The compa…
Birchtech Corp. announced its fourth quarter and full year 2025 financial results, highlighting a 19.8% year-over-year increase in product revenues and a $0.8 million improvement in net loss. The company successfully uplisted to the NYSE American in February 2026, raising $16.6 million to enhance its financial position. Additionally, Birchtech secu…
Maase Inc. (NASDAQ: MAAS) finalized its acquisition of Huazhi Future, marking a strategic transition from a scenario operator to an AI industry player with integrated full-stack AI capabilities. The acquisition enables MAAS to combine computing infrastructure, proprietary AI algorithms, intelligent hardware, and operational services into a comprehe…
Minerva Neurosciences has begun screening the first patient in its global Phase 3 confirmatory trial of roluperidone, a drug candidate designed to treat negative symptoms of schizophrenia such as avolition, anhedonia, and social withdrawal—symptoms for which there are currently no FDA-approved therapies. The trial plans to enroll approximately 380 …
Tenaris S.A., a leading global supplier of steel tubes for the energy sector and other industries, filed its 2025 Annual Report with the Luxembourg Stock Exchange and other regulators, including the U.S. SEC. The report includes consolidated financial statements, sustainability information, and auditor certifications. The Form 20-F will be filed wi…
SPAR Group, Inc. announced its financial guidance for fiscal year 2026, projecting net sales between $143 million and $151 million, and gross margins improving to 20.5%-22.5%. The company highlighted a favorable shift towards higher-margin core merchandising services, cost reductions, ongoing AI implementation for efficiency, and recent capital rai…
Fortress Biotech announced its full year 2025 financial results, highlighted by FDA approval of ZYCUBO® to treat Menkes disease, the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, and the acquisition of subsidiary Checkpoint Therapeutics by Sun Pharma which established a long-term royalty stream. The company showed impro…
Oculis Holding AG announced that the European Medicines Agency granted Priority Medicines (PRIME) designation to its neuroprotective candidate Privosegtor for optic neuritis (ON), following a prior FDA Breakthrough Therapy designation. Supported by positive Phase 2 trial results demonstrating significant improvements in visual function and neuropro…
Workhorse Group Inc. announced its fourth quarter and full year 2025 financial results, marking its first earnings report after merging with Motiv Electric Trucks. The company reported a 64% revenue increase in Q4 and a 201% rise for the full year, driven by vehicle deliveries and product lineup expansion. Workhorse is targeting $20 million in annu…
Nano Dimension Ltd. announced its financial results for Q4 and full year 2025, highlighting a 77.3% year-over-year revenue increase to $102.4 million driven partly by the acquisition of Markforged. Despite revenue growth and improved adjusted gross margins, the company reported a net loss of $100.4 million for the year. Cost reduction efforts are u…
ORIC Pharmaceuticals announced the selection of 400 mg once daily rinzimetostat (ORIC-944) in combination with darolutamide as the recommended Phase 3 dose (RP3D) for the Himalayas-1 global Phase 3 registrational trial in post-abiraterone metastatic castration-resistant prostate cancer (mCRPC). Phase 1b data show favorable safety and promising effi…
authID Inc. reported its financial results for Q4 and full year 2025 showing revenue growth but increased net losses. Total revenue doubled in the year to $2.0 million, though net loss increased to $17.9 million. The company highlighted significant new contracts and pilot deployments with global retailers, financial institutions, and technology par…
